ArticleJournal of basic microbiology2026
Mycobacteriophage Mcgavigan Uses Noncanonical Bxb1-Like Repressor for Heterotypic Superinfection Immunity.
Article in Journal of basic microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mycobacteriophage Mcgavigan Uses Noncanonical Bxb1-Like Repressor for Heterotypic Superinfection Immunity.Journal of basic microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Mycobacteriophage Mcgavigan could be a promising candidate for use as a preventative agent against infections with Mycobacterium avium subsp. paratuberculosis. Bioinformatic analysis of the Mcgavigan genome revealed the presence of an operon containing a "Bxb1-like" repressor. The operon may have been acquired by the phage through horizontal gene transfer with a Bxb1-like mycobacteriophage in its evolutionary past. We sought to investigate the function of the acquired repressor as a potential regulator of lysogeny or as a source of heterotypic superinfection immunity. Recombineering with CRISPR counter-selection was employed to achieve a clean deletion of the Bxb1-like repressor from Mcgavigan's genome. Integrase was also deleted as a means of creating a lytic-only phage for comparison purposes and the elimination of lysogeny with this edit was confirmed. To test phenotypic changes which resulted from these deletions, several parameters such as burst size, latency period, and killing efficiency were measured for each knockout mutant and lysogeny was tested. The integrase deletion mutant had complete lysogeny abolishment and performed similarly to wild-type phage on all measured parameters. The deletion of the Bxb1-like repressor did not affect the lysogenic capability of the phage. Whereas Mcgavigan lysogens are typically immune to superinfection from Terelak, a mycobacteriophage related to Bxb1, lysogens created from Mcgavigan with the Bxb1-like repressor deletion were completely resensitized to heterotypic superinfection by Terelak. This suggested that this repressor was acquired by Mcgavigan through horizontal gene transfer for the purposes of superinfection immunity against cluster A1 mycobacteriophages and was not used for maintenance of lysogeny.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.